At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 84 enrolled
Drug / intervention
PF-05231023 +7 moredrug
Likely dose
PF-05231023 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Placebo-controlled, Randomized Study To Assess The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Following Single, Escalating Intravenous Doses Of Pf-05231023 In Adult Subjects With Type 2 Diabetes
In Brief
A Phase 1 clinical trial evaluating PF-05231023 and Placebo for Diabetes Mellitus, Type 2. Completed, enrolled 84 participants across 5 sites.
Detailed Summary
This is a trial in subjects with Type 2 diabetes mellitus to study the safety, tolerability and pharmacokinetics and pharmacodynamics of single escalating doses of PF-05231023.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedJan 2011
Enrollment StartFeb 2011
Primary CompletionJul 2011
TodayJul 2026
First PostedJan 28, 2011
Enrollment StartFeb 1, 2011
Primary CompletionJul 1, 2011
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 15.4 years ago
Interventions
PF-05231023drug
0.5 mg QD IV x 1 day
PF-05231023drug
1.5 mg QD IV x 1 day
PF-05231023drug
5 mg QD IV x 1 day
PF-05231023drug
15 mg QD IV x 1 day
PF-05231023drug
50 mg QD IV x 1 day
PF-05231023drug
100 mg QD IV x 1 day
PF-05231023drug
200 mg QD IV x 1 day
Placeboother
0.9% w/v sodium chloride injection, USP QD IVx 1 day